(Q38770371)

6 September 2017

Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy (English)

1 reference

6 September 2017

1 reference

Eugene J Pietzak

1

1 reference

PubMed ID

26968417

6 September 2017

James A Eastham

series ordinal

2

1 reference

6 September 2017

1 May 2016

1 reference

6 September 2017

Current urology reports

1 reference

6 September 2017

17

1 reference

6 September 2017

37

1 reference

6 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s11934-016-0592-4

6 September 2017

0 references

cites work

The status of surgery in the management of high-risk prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

High-risk prostate cancer-classification and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Duration of androgen suppression in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Radical prostatectomy versus observation for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Advances in the multimodality management of high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Locally advanced prostate cancer: a population-based study of treatment patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Androgen receptor signaling regulates DNA repair in prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Enzalutamide in metastatic prostate cancer before chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

The future of systemic therapies for localised prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Experience with degarelix in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Microtubule-binding agents: a dynamic field of cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Therapy escape mechanisms in the malignant prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk local

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Trial watch: phase II and phase III attrition rates 2011-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

The mutational landscape of lethal castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

The Molecular Taxonomy of Primary Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Integrative clinical genomics of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-016-0592-4

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer

21 January 2018

1 reference

12 December 2020

Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System

1 reference

12 December 2020

Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects

1 reference

12 December 2020

Prostate cancer, version 2.2014

1 reference

12 December 2020

Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor

1 reference

12 December 2020

Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results

1 reference

12 December 2020

Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study

1 reference

12 December 2020

10.1007/S11934-016-0592-4

Identifiers

DOI

1 reference

PubMed ID

26968417

Dimensions Publication ID

6 September 2017

0 references

1 reference

PubMed ID

26968417